# THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)

Study · id `cardio:ct-nct02002325` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02002325](<https://clinicaltrials.gov/study/NCT02002325>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02002325

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT02002325. Randomized; single masking; primary purpose treatment. Start 2014-05 (actual); primary completion 2019-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT02002325, source copy `cardio:ctgov-nct02002325-2018-12-20`, retrieved 2026-10-26)
- Started: 2014-05 (actual) (ClinicalTrials.gov record NCT02002325, source copy `cardio:ctgov-nct02002325-2018-12-20`, retrieved 2026-10-26)
- Primary completion: 2019-12 (anticipated) (ClinicalTrials.gov record NCT02002325, source copy `cardio:ctgov-nct02002325-2018-12-20`, retrieved 2026-10-26)
- Completion: 2020-03 (anticipated) (ClinicalTrials.gov record NCT02002325, source copy `cardio:ctgov-nct02002325-2018-12-20`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02002325, source copy `cardio:ctgov-nct02002325-2018-12-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02002325-2018-12-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)
- Acronym: THAWS
- Condition: Stroke
- Intervention (Drug): Tissue-type plasminogen activator (alteplase)
- Intervention (Other): Standard care
- Lead sponsor: National Cerebral and Cardiovascular Center, Japan
- Lead sponsor class: OTHER
- Collaborator: Charitable Trust Mihara Cerebrovascular Disorder Research Promotion Fund
- Collaborator class: UNKNOWN
- Collaborator: Japan Agency for Medical Research and Development
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: National Cerebral and Cardiovascular Center, Japan (`cardio:org-national-cerebral-and-cardiovascular-center-japan`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial (`cardio:pubmed-32248771`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Magnetic Resonance Imaging-Guided Thrombolysis (0.6 mg/kg) Was Beneficial for Unknown Onset Stroke Above a Certain Core Size: THAWS RCT Substudy (`cardio:pubmed-33297866`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Associations between fluid-attenuated inversion recovery vessel hyperintensities and Alberta stroke program early CT score and clinical outcomes in stroke patients with unknown time of onset: A sub-analysis from a randomized controlled trial (`cardio:pubmed-40884089`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e7e17ef89a9c279a5753a6421bf7105662482d13e8648ec067094df29b6bcae9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
